Brain Organoid Consciousness: The Evidence, a Test, and the Law

Brain organoid consciousness is a question nobody can currently answer with data, and that is the honest starting point. Organoids are millimetre-scale clumps of human neural tissue grown from stem cells. They fire, they synchronise, and in a few labs they now sit inside rat brains and respond to whisker touches. Whether any of that activity could ever be accompanied by experience, even a flicker of it, is unsettled. So is the narrower practical question: if it could, would anyone be able to tell?

This article separates what has been measured from what has been argued. It then puts one widely used clinical marker of consciousness through a small computational test, sketches what a defensible assay would require, and surveys how the United States, the United Kingdom and international guidance currently treat the research. This is general information, not legal advice.

Why the question keeps coming back

Public interest is real, not manufactured. A Live Science piece headlined “Tiny ‘brains’ grown in the lab could become conscious and feel pain — and we’re not ready” was picked up on Reddit’s r/Futurology, where the comments I read circled the same handful of doubts: do we even know how consciousness works in an intact brain, what would a disconnected piece of tissue have to be aware of, and can something with no pain receptors suffer at all? One commenter argued the worry was out of proportion next to the billions of farmed animals whose sentience is not in doubt.

Those are good questions, and researchers ask versions of them too. The stakes cut both ways. If organoids can never be conscious, elaborate oversight wastes money and slows work on autism, epilepsy and neurodevelopmental disease. If some future preparation can, the field risks creating a subject of moral concern inside an incubator with no protocol for noticing.

What organoids have been shown to do

Three findings anchor the debate, and none of them is a claim about experience.

First, spontaneous network activity. Trujillo and colleagues grew human cortical organoids for about ten months and recorded them on multi-electrode arrays (Trujillo et al. 2019, published in Cell Stem Cell). Around two months, the tissue produced network bursts roughly every 20 seconds with almost clockwork timing. From about four months, nested 2–3 Hz oscillations appeared inside those bursts, and the timing grew more irregular as the cultures aged. A machine-learning model trained on 567 EEG recordings from preterm infants, using nine features, predicted an organoid “age” that tracked actual culture age after roughly 28 weeks. That is a resemblance in a handful of statistical features, not a demonstration that the organoid resembles an infant in any further respect.

Second, integration with a living brain. Revah et al. (2022) transplanted human cortical organoids into the somatosensory cortex of newborn rats. The grafts matured further than dish-grown controls, received thalamocortical input from the host, and a subset of human neurons increased firing after whisker deflection. When the grafted cells were driven optogenetically (the light-switch technique described in our explainer on the optogenetics Nobel), trained rats learned to seek a reward. The human tissue was, in a limited sense, part of the animal’s behaviour.

Third, explicit computing ambitions. A 2023 roadmap in Frontiers in Science (Smirnova et al. 2023) proposed “organoid intelligence” as a biocomputing field, while stating that the programme “does not aim to recreate human consciousness.” Aims, of course, do not constrain outcomes.

What is not established: any organoid showing a measured marker that clinicians would accept as evidence of awareness in a patient. Nobody has published one. The reason is partly biological and partly methodological, and the methodological part deserves attention.

How consciousness is measured when nobody can answer

Doctors face a version of this problem every week with patients who cannot speak or move. The best-validated tool for them is the perturbational complexity index, or PCI. A magnetic pulse (TMS) is applied to the cortex, high-density EEG records the echo, and the significant part of the response is compressed with a Lempel-Ziv algorithm. A brain that responds with activity that is both widespread and varied scores high. One that responds locally, or with a single stereotyped wave, scores low. Our post on what anesthesia does to the brain covers why this integration-plus-differentiation idea took hold.

The numbers come from human data. In the original study (Casali et al. 2013, Science Translational Medicine), PCI fell to values between 0.12 and 0.31 when subjects lost consciousness.

Every conscious condition scored above that ceiling. Casarotto et al. (2016) then calibrated an empirical cutoff on 150 healthy controls and communicative brain-injured patients, reporting 100% sensitivity and specificity in that benchmark and 94.7% sensitivity for detecting minimally conscious patients. Nine of 43 vegetative-state patients scored above the cutoff, which the authors read as a possible hidden capacity for consciousness. The widely cited cutoff value is 0.31; the abstract I could access does not print the number, so treat that figure as Casali’s ceiling rather than a verified restatement of Casarotto’s threshold.

Two features of this tool matter for organoids. It was validated on adult human cortex with a skull, scalp electrodes and a known ground truth (people who could later report). And its output is a normalised number whose meaning depends on the size of the system, the recording grid, the time window and the statistics used to decide which responses count.

Four competing answers

Steelmanned, the positions in the literature sort roughly as follows. The labels are mine.

1. Not now, and not soon

Current organoids lack thalamocortical loops, sensory input, motor output and the homeostatic machinery a body supplies. The report of the 2025 Asilomar meeting on organoid oversight states this view: present-day organoids are unlikely to have morally relevant capacities, partly for those structural reasons (Asilomar Conference report 2026). The evidence for it is anatomical and fairly strong. Its weakness is that it is a claim about today’s preparations, and assembloids and transplants are already adding the missing parts one at a time.

2. Premature skepticism

Wood et al. (2025), writing in Patterns, argue that the post-2020 consensus against organoid consciousness rests on contestable premises: that low structural complexity rules it out, that a body is required, and that expert agreement settles the matter. Their conclusion is pointed:

“We caution against enshrining such skepticism into dogma or using it to defer ethical engagement.”

Wood, Wang, Yang and Xi, 2025, Patterns

The strength here is philosophical: several leading theories do not require a body or a sensory stream. The weakness is that no organoid measurement has yet given the argument an empirical foothold.

3. Theory decides, and theories disagree

Integrated information theory, which motivated PCI, ties consciousness to a system’s intrinsic causal structure, so in principle an isolated tissue could qualify. Global workspace accounts tie it to broadcast across specialised modules, which a small organoid probably lacks. Higher-order theories demand self-monitoring of a kind no organoid plausibly has. On this view the organoid question cannot be answered until the broader theory of consciousness is, which may mean a long wait.

4. Islands are possible but unmeasurable

A fourth position concedes that a disconnected neural system might host experience yet doubts any external test could confirm it. Lavazza and Massimini (2018) proposed adapting PCI to organoids with optogenetic stimulation and calcium imaging, and immediately named the obstacle:

“Clearly, the problem would still be how to validate this new index and identify a valid operational cut-off”

Lavazza and Massimini, 2018, Journal of Medical Ethics

That sentence is the bridge to the experiment below.

A small simulation: complexity scores on networks that cannot be conscious

To see how portable a PCI-style threshold is, I built a toy model for this article. It is not a model of an organoid and certainly not of a brain. Sixty-four probabilistic excitable units sit in eight modules of eight. Each unit fires spontaneously at a low rate, can be excited by active neighbours, and then goes refractory for four steps. A “pulse” forces four units in one module to fire. Each condition runs 150 trials; the trial-averaged response is thresholded against the pre-pulse baseline to get a binary matrix of significant activity, and that matrix is scored with the Lempel-Ziv normalisation Casali et al. used. I varied only the wiring between modules and the significance rule, ran ten networks per condition with a fixed seed, and recorded how many modules the response reached.

import numpy as np
def lz76(s):  # Lempel-Ziv (1976) complexity, Kaspar-Schuster algorithm
    n=len(s); i,k,l,c,kmax=0,1,1,1,1
    while True:
        if s[i+k-1]==s[l+k-1]:
            k+=1
            if l+k>n: c+=1; break
        else:
            kmax=max(k,kmax); i+=1
            if i==l:
                c+=1; l+=kmax
                if l+1>n: break
                i,k,kmax=0,1,1
            else: k=1
    return c
def pci(SS):  # normalisation of Casali et al. 2013: LZ*log2(L)/(L*H(p))
    s=SS.T.flatten(); L=len(s); p=s.mean()
    if p in (0,1): return 0.0
    H=-p*np.log2(p)-(1-p)*np.log2(1-p)
    return lz76(s.tolist())*np.log2(L)/(L*H)
def network(w_in,w_out,M=8,K=8):  # 8 modules x 8 excitable units
    mod=np.repeat(np.arange(M),K); W=np.where(mod[:,None]==mod[None,:],w_in,w_out)
    np.fill_diagonal(W,0); return W
def run(W,rng,fw,trials=150,pre=60,post=60,spont=0.004,refr=4):
    N=len(W); act=np.zeros((trials,N),bool); ref=np.zeros((trials,N),int)
    X=np.zeros((pre+post,trials,N),bool)
    for t in range(pre+post):
        p=1-np.exp(np.log1p(-W)@act.T.astype(float)).T   # input from active units
        new=(rng.random((trials,N))<1-(1-p)*(1-spont))&(ref==0)
        if t==pre: new[:,:4]=True                  # the "pulse": 4 units of module 0
        ref=np.maximum(ref-1,0); ref[new]=refr; act=new; X[t]=new
    m=X.mean(1)                                    # trial-averaged response
    thr=m[:pre].max() if fw else np.percentile(m[:pre],99.5,axis=0)
    SS=(m[pre:]>thr+1e-9).T                        # significant units x time
    reach=len(set(np.where(SS[:,1:].any(1))[0]//8))
    return pci(SS), SS.mean(), reach
rng=np.random.default_rng(14)
conds={"noise only":(0,0),"isolated modules":(.3,0),"modular, weak links":(.3,.02),
       "modular, medium links":(.3,.05),"dense, strong links":(.3,.3)}
for fw in (False,True):
    for name,(a,b) in conds.items():
        v=np.array([run(network(a,b),rng,fw) for _ in range(10)])
        print(fw,name,np.round(v.mean(0),3),round(v[:,0].std(),3))

Results from that run (mean of ten networks per condition; the standard deviation is in brackets):

Three things fall out. With the strict rule, the expected ordering appears where responses are large: modular wiring with medium links reached all eight modules and scored 0.378, while dense wiring, which turns every pulse into one stereotyped burst, also reached everything but scored 0.158. That is the integration-versus-differentiation logic behind PCI, reproduced in a system of 64 dots.

Second, under the strict rule every condition except the burst-like one landed above 0.31, including pure noise. The reason is mechanical. When almost nothing is significant (0.1% of the matrix in the noise case), dividing by the entropy of that sparse matrix inflates the score. The clinical protocol avoids this through large responses, source modelling and careful statistics, conditions that a toy, or a new preparation, may not meet. Third, the significance rule alone moved scores by up to 0.25 within the same wiring.

What this shows: a PCI-style number is not substrate-neutral. Its value depends on network size, response size and analysis choices, so the human cutoff cannot simply be transplanted to an organoid recording. What it does not show: anything about whether organoids are or could be conscious, or that PCI is flawed in its validated clinical use. Organoid bursts as Trujillo described them look closer to my stereotyped condition than the differentiated one, but that is a qualitative resemblance, not a measurement.

What a responsible test would look like

Pulling the threads together, a defensible assay would need at least five elements. None is exotic; the combination has not been attempted.

• Calibration ladder. Score the same pipeline on preparations with known status: acute human or rodent cortical slices, anaesthetised versus awake rodents with comparable electrode grids, and organoids at several ages. Set any cutoff on that ladder, not on adult TMS-EEG.
• Matched recording geometry. Fix electrode count, sampling and response window before data collection, because the simulation shows the normalised score shifts with them.
• Strict significance and null models. Family-wise control, plus shuffled and spatially scrambled surrogates, with a minimum response size below which no score is reported.
• Multiple markers. Pair perturbational complexity with spontaneous-activity measures (state transitions, sleep-like slow oscillations and their absence) and with pharmacology: an anaesthetic that drops human PCI should drop the organoid’s score too if the comparison means anything.
• Pre-registration and review triggers. Publish the analysis plan in advance and agree, before the data arrive, what result would prompt ethical review. The Asilomar report recommends exactly such triggers.

A clean negative from that design would not prove absence of experience. It would show that the organoid lacks the signature that tracks consciousness in humans, which is the strongest kind of evidence available.

What the law says in the US, the UK and beyond

United States. No statute addresses neural organoids. The federal Common Rule governs research on human subjects, defined in 45 CFR 46.102(e)(1) as a living individual about whom an investigator collects data through interaction or who:

“Obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens.”

45 CFR 46.102(e)(1)(ii)

On the usual reading, organoids made from de-identified cell lines therefore fall outside the Rule, and the organoid itself is not a “living individual” in the regulation’s sense. Oversight in practice runs through institutional review boards for donor consent, animal care committees for transplants, and stem cell research oversight committees, with professional guidelines that funders and journals may require. The Asilomar report describes this patchwork and notes that research proceeds under varying frameworks in different countries.

United Kingdom. The Human Tissue Act 2004 regulates “relevant material,” defined in section 53 as material other than gametes that consists of or includes human cells. Donor consent is the main hook. The Human Fertilisation and Embryology Act 1990 does not reach organoids: section 1 defines an embryo as a live human embryo, and an organoid is not one. Transplanting human neural tissue into animals falls under animal-research licensing and is addressed by Home Office guidance on human material in animals. In May 2026 the Nuffield Council on Bioethics reported “significant governance gaps,” recommending best-practice guidance, an update to that Home Office guidance for neural transplants, a review of donor consent, central monitoring, and public engagement on possible red lines (NCOB 2026).

International soft law. The ISSCR Guidelines (2021, with an August 2025 update focused on embryo models) are the main transnational reference; they are professional standards, not law. The Asilomar organisers, Sergiu Pașca and Hank Greely, recommend a decentralised international oversight process with monitoring and review triggers, and explicitly advise against rigid bright-line bans for now (Stanford Report 2026). I did not verify organoid-specific rules in other jurisdictions and make no claim about them.

The net position, as a matter of fact: in neither country does an organoid have legal interests of its own. Protections attach to donors and, once transplanted, to host animals.

The author’s reading, and what would settle it

What follows is opinion. I think hypothesis 1 is right about present organoids and hypothesis 2 is right about the reasoning. The anatomical case against current consciousness is decent, but it is a snapshot, and the field is deliberately adding thalamic input, vascularisation and host integration. Meanwhile the main empirical tool people invoke, a complexity cutoff, does not transfer without recalibration, as even a 64-unit toy illustrates.

Specific predictions that would move the debate:

• If a calibrated perturbational measure is applied to dish-grown cortical organoids, scores will stay below the range of awake rodent cortex recorded with the same grid. A score inside that range, robust to null models, would falsify the comfortable version of hypothesis 1.
• Transplanted organoids that receive thalamic input will show state-dependent changes, higher complexity in the awake host than under anaesthesia. If grafted tissue tracks the host’s state, the islands question (hypothesis 4) partly dissolves, because the tissue is no longer an island.
• Assembloids that add thalamic and cortical parts will show more differentiated perturbation responses than single-region organoids of the same age. No difference would weaken the structural argument both camps rely on.
• Within five years, a funder or journal will require a pre-registered consciousness-relevant assay for organoid studies above some threshold of size or connectivity. If none does, the review-trigger proposals will have stayed on paper.

The most useful single study would be the calibration ladder above, run by a lab that also does clinical PCI, with data released openly.

Common questions

Are brain organoids conscious right now?

There is no evidence that any existing organoid is conscious, and most researchers think it unlikely given missing inputs, outputs and thalamocortical circuitry. That is a judgment, not a measurement; no validated test for organoids exists yet.

Can a brain organoid feel pain?

Pain as people experience it involves sensory nerves, spinal pathways and many brain regions that organoids lack. A transplanted organoid receiving input from a host animal is a different case, which is why the UK and Asilomar recommendations focus on transplantation.

Is research on brain organoids legal?

Yes, in the US and UK it is lawful and governed mainly through donor-consent rules, institutional review and animal-research licensing. Neither country has a statute specific to neural organoids.

Could the clinical consciousness test be used on an organoid?

Not directly. The perturbational complexity index was calibrated on adult human brains with TMS and scalp EEG, and its numerical cutoff depends on recording setup and system size. It would need a new calibration, which is what Lavazza and Massimini flagged in 2018.

Further reading

• Sizing Up Consciousness: Towards an Objective Measure of the Capacity for Experience by Marcello Massimini and Giulio Tononi. Written by the developers of the perturbational complexity index, it explains the measurement approach the article tests. See it on Amazon (affiliate link)
• Being You: A New Science of Consciousness by Anil Seth. A readable account of current consciousness science and why measuring it in non-standard systems is hard. See it on Amazon (affiliate link)

As an Amazon Associate I earn from qualifying purchases. A commission may be earned if you buy through this link, at no extra cost to you.

References

1. Casali, A. G., Gosseries, O., Rosanova, M., Boly, M., Sarasso, S., Casali, K. R., Casarotto, S., Bruno, M.-A., Laureys, S., Tononi, G., and Massimini, M. (2013). A theoretically based index of consciousness independent of sensory processing and behavior. Science Translational Medicine, 5(198), 198ra105. Author copy
2. Casarotto, S., Comanducci, A., Rosanova, M., et al., and Massimini, M. (2016). Stratification of unresponsive patients by an independently validated index of brain complexity. Annals of Neurology, 80(5), 718–729. doi:10.1002/ana.24779. Repository record
3. Trujillo, C. A., et al., and Muotri, A. R. (2019). Complex oscillatory waves emerging from cortical organoids model early human brain network development. Cell Stem Cell, 25(4), 558–569. Earlier version as preprint: bioRxiv 10.1101/358622
4. Revah, O., et al., and Pașca, S. P. (2022). Maturation and circuit integration of transplanted human cortical organoids. Nature, 610, 319–326. Nature
5. Smirnova, L., et al., and Hartung, T. (2023). Organoid intelligence (OI): the new frontier in biocomputing and intelligence-in-a-dish. Frontiers in Science. Frontiers
6. Lavazza, A., and Massimini, M. (2018). Cerebral organoids: ethical issues and consciousness assessment. Journal of Medical Ethics, 44(9), 606–610. JME
7. Wood, C., Wang, H., Yang, W., and Xi, Y. (2025). Facing the possibility of consciousness in human brain organoids. Patterns, 6(9). doi:10.1016/j.patter.2025.101365. ORA record
8. Pașca, S. P., and Greely, H. T. (organisers); Worldview Studio (rapporteur) (2026). Full report: 2025 Asilomar Conference on Oversight of Neural Organoids. Wu Tsai Neurosciences Institute and Dana Foundation. PDF
9. Stanford Report (2 September 2026). News article on the Asilomar framework for brain organoid research. Stanford News
10. Nuffield Council on Bioethics (2026). Neural organoids: ethical and governance considerations. Publication page; press statement: NCOB news
11. Protection of Human Subjects, 45 C.F.R. § 46.102 (definitions). eCFR
12. Human Tissue Act 2004, c. 30, s. 53 (UK). legislation.gov.uk
13. Human Fertilisation and Embryology Act 1990, c. 37, s. 1 (UK). legislation.gov.uk
14. Home Office (2016, updated). Guidance on the use of human material in animals. GOV.UK
15. International Society for Stem Cell Research (2021; update August 2025). ISSCR Guidelines for Stem Cell Research and Clinical Translation. ISSCR
16. Live Science (n.d.). Tiny ‘brains’ grown in the lab could become conscious and feel pain — and we’re not ready. Live Science